WuXi Biologics Introduces the WuXia293 Cell Line Platform
WuXia293: A Game-Changer in Biologics Development and Manufacturing
WuXi Biologics, a leading global biologics company, has announced the launch of its new platform, WuXia293, designed for the development and manufacturing of difficult-to-express biologics in HEK293 cells. This innovative platform promises to accelerate the delivery of innovative biologics to patients worldwide.
The WuXia293 platform offers several advantages over traditional CHO (Chinese Hamster Ovary) cell expression systems. It is based on the HEK293 stable cell line, which provides human-like glycosylation patterns, improving the quality and efficacy of complex biologics compared to CHO cells.
WuXia293 achieves high expression titers up to 5.0 g/L for monoclonal antibodies, competitive with or exceeding traditional CHO titers. Moreover, the platform significantly reduces or eliminates truncation issues commonly observed in complex biologics expressed in CHO cells, improving product purity and quality.
The platform supports stable expression over long-term cell passages, ensuring consistency across development and manufacturing runs. It allows scalable manufacturing with fed-batch processes up to 2,000 liters and perfusion processes up to 1,000 liters, enabling commercial-scale production while maintaining quality.
WuXia293 is integrated into WuXi Biologics’ comprehensive one-stop CMC services, including cell bank testing and viral clearance validation, streamlining biologics development timelines.
Dr. Chris Chen, CEO of WuXi Biologics, commented on the launch of WuXia293, expressing excitement for its potential to enhance the development of advanced therapeutics. The new platform offers a highly efficient CMC solution for biologics that are sophisticated in both structure and function.
The launch of WuXia293 has further strengthened the service capabilities of WuXi Biologics' WuXiaTM platform family. It stands as a powerful testament to WuXi Biologics' unwavering commitment to its vision that every biologic can be made.
[1] Data on file, WuXi Biologics.
